Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab Consolidation in Limited-Stage SCLC
NCT04418648Phase 2Terminated
- Sponsor
- Sun Yat-sen University
- Start
- Jun 2020
- Primary completion
- May 2024
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of toripalimab in small cell lung cancer (SCLC), sponsored by Sun Yat-sen University. Started Jun 2020; status: terminated.
02
Drugs
toripalimab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT04418648.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04418648.